News for Corvus Pharmaceuticals, Inc. (CRVS)

Published at

Apr 10, 2025 12:00 AM

by gurufocus.com

mixed

mixed

Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors

SOUTH SAN FRANCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. ( CRVS), a clinical-stage biopharmaceutical company, announced to

PLSE CRVS

Read more →
Published at

Apr 9, 2025 10:19 PM

by manilatimes.net

neutral

neutral

Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors

**media[590863]**

PLSE CRVS

Read more →
Published at

Mar 28, 2025 2:30 PM

by seekingalpha.com

neutral

neutral

Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials

Corvus Pharmaceuticals suffered lately, especially after it announced in December 2024 its early AD data. Check out why I rate CRVS stock as a Hold.

CRVS

Read more →
Published at

Mar 27, 2025 1:05 PM

by insidermonkey.com

positive

positive

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2024 Earnings Call Transcript

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2024 Earnings Call Transcript March 25, 2025Corvus Pharmaceuticals, Inc. misses on earnings expectations.

CRVS

Read more →
Published at

Mar 26, 2025 12:58 AM

by seekingalpha.com

neutral

neutral

Corvus Pharmaceuticals outlines clinical milestones for soquelitinib in 2025 (NASDAQ:CRVS)

Discover Corvus Pharmaceuticals' Q4 2024 earnings insights, highlighting soquelitinib's trial progress, upcoming milestones for 2025, and robust financial...

CRVS

Read more →
Published at

Mar 26, 2025 12:58 AM

by seekingalpha.com

positive

positive

Corvus Pharmaceuticals, Inc. (CRVS) Q4 2024 Earnings Call Transcript

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2024 Earnings Conference Call March 25, 2025 4:30 PM ETCompany ParticipantsZack Kubow - Real Chemistry, IRLeiv...

CRVS

Read more →
Published at

Mar 25, 2025 9:22 PM

by manilatimes.net

negative

negative

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

**media[576504]**

CRVS

Read more →
Published at

Mar 20, 2025 2:00 PM

by gurufocus.com

neutral

neutral

Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma

Data to be presented in oral session and poster at the 16th Annual T-Cell Lymphoma Forum SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Cor

CRVS

Read more →
Published at

Mar 20, 2025 1:19 PM

by manilatimes.net

neutral

neutral

Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma

**media[571861]**

CRVS

Read more →
Published at

Mar 19, 2025 9:11 PM

by manilatimes.net

neutral

neutral

Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

**media[571349]**

CRVS

Read more →
Published at

Mar 17, 2025 11:00 PM

by gurufocus.com

negative

negative

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT SOUTH SAN FRANCISCO, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceutical

CRVS

Read more →
Published at

Mar 12, 2025 2:00 PM

by gurufocus.com

negative

negative

Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS)

Trial for this rare genetic disease to be conducted by NIH/NIAID in partnership with Corvus ITK inhibition intended to address dysregulation of T cells that ca

CRVS

Read more →
Published at

Mar 3, 2025 6:59 PM

by seekingalpha.com

positive

positive

Corvus Pharmaceuticals: Small Market, Many Competitors, Low Cash Balance (NASDAQ:CRVS)

Corvus Pharmaceuticals' Soquelitinib shows promise for PTCL & more, but financial risks and competition raise concerns. Learn more about CRVS stock here.

CRVS

Read more →
Published at

Feb 14, 2025 11:15 PM

by gurufocus.com

positive

positive

Samlyn Capital, LLC Increases Stake in Corvus Pharmaceuticals Inc.

On December 31, 2024, Samlyn Capital, LLC executed a significant transaction by acquiring an additional 2,136,772 shares of Corvus Pharmaceuticals Inc. This acq

MSFTD.BA MSFTCL.SN MSFTC.BA MSFTB.BA MSFT.MI LPLA FSLR34.SA FSLR.MX FSLR.BA FSLR F3A.DE CRVS 0R06.L

Read more →
Published at

Feb 14, 2025 3:11 PM

by gurufocus.com

positive

positive

ADAMS STREET PARTNERS LLC Reduces Stake in Mineralys Therapeutics Inc

On December 31, 2024, ADAMS STREET PARTNERS LLC (Trades, Portfolio) made a strategic decision to reduce its position in Mineralys Therapeutics Inc (MLYS) by 402

RMNIW RMNI QTWO.MX QTWO CRVS

Read more →
Published at

Jan 13, 2025 1:47 PM

by manilatimes.net

negative

negative

Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

**media[513456,513457]**

CRVS

Read more →
Published at

Jan 7, 2025 11:00 PM

by gurufocus.com

negative

negative

Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

BURLINGAME, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. ( CRVS), a clinical-stage biopharmaceutical company, today announced that R

CRVS

Read more →
Published at

Jan 2, 2025 7:48 PM

by seekingalpha.com

positive

positive

Corvus stock wins new buy at H.C. Wainwright (CRVS:NASDAQ)

Corvus Pharmaceuticals (CRVS) stock was granted a new buy recommendation by H.C. Wainwright based on its lead asset, despite its recent selloff. Read more here.

CRVS

Read more →
Published at

Dec 18, 2024 7:36 PM

by seekingalpha.com

positive

positive

Corvus Pharmaceuticals: Not Just A One-Hit Wonder In ITK Inhibitor Targeting (CRVS)

Corvus Pharmaceuticals develops next-gen ITK inhibitors, with promising Phase 1 results. Read why CRVS stock can thrive in the $22.6B Atopic Dermatitis market.

CRVS

Read more →
Published at

Dec 18, 2024 6:26 PM

by benzinga.com

mixed

mixed

Crude Oil Gains Over 1%, General Mills Shares Fall - General Mills (NYSE:GIS), Corvus Pharma (NASDAQ:CRVS)

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 150 points on Wednesday. The Dow traded up 0.52% to 43,674.00 while t...

KULR HEI-A HEI H1EI34.SA GRM.DE GIS.MX GIS 0R1X.L 0J46.L CRVS

Read more →